ARTICLE | Deals
Sosei Heptares gains new GPCR discovery partner in AbbVie
June 26, 2020 1:05 AM UTC
Updated on Jun 27, 2020 at 2:32 AM UTC
Sosei Heptares’ GPCR-targeting platform is continuing to draw attention from pharma with a deal with AbbVie that follows 2019 discovery collaborations with Genentech and Takeda.
The Sosei Group Corp. (Tokyo:4565) unit will use its StaR platform to discover small molecules against GPCR targets chosen by AbbVie Inc. (NYSE:ABBV) and take the compounds through IND-enabling studies. If AbbVie exercises its options for exclusive rights, it will be responsible for global development and commercialization. ...